Journal of Biosciences and Medicines

Volume 12, Issue 3 (March 2024)

ISSN Print: 2327-5081   ISSN Online: 2327-509X

Google-based Impact Factor: 0.51  Citations  

A Comprehensive Review of Exosomes with Therapeutic Potential in Cancer and Coeliac Disease

HTML  XML Download Download as PDF (Size: 1636KB)  PP. 25-34  
DOI: 10.4236/jbm.2024.123003    47 Downloads   282 Views  

ABSTRACT

The aim of this review was to evaluate the therapeutic potential of exosomes, extracellular vesicles secreted by cells. They have emerged as potential therapeutic transporters for several diseases. This review provides an overview of exosomes’ therapeutic potential in cancer therapy and autoimmune conditions such as Coeliac Disease. The therapeutic effect is that the phospholipid-binding protein ANXA1 improves its anti-inflammatory properties. The review also analyzes the intricate processes of exosome production and composition ability to transport biomolecules such as proteins, microRNAs, and lipids, which promote intercellular communication and alter recipient cell behavior. Exosomes, linked to neurological disorders, cardiovascular disease, and cancer, present the means of targeted drug administration due to their innate specificity. Through genetic engineering and chemical modifications, exosomes can be tailored for specific purposes, demonstrating their versatility in targeted therapy. With ongoing research uncovering their therapeutic potential, exosomes present a promising frontier in novel medical treatments across various health conditions.

Share and Cite:

Assainar, F. , Thomas, J. , Saleem, Z. , Thekkekara, S. , Mammoo, F. and Kallan, N. (2024) A Comprehensive Review of Exosomes with Therapeutic Potential in Cancer and Coeliac Disease. Journal of Biosciences and Medicines, 12, 25-34. doi: 10.4236/jbm.2024.123003.

Cited by

No relevant information.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.